Legend BiotechLEGN
LEGN
About: Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Employees: 2,700
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
6% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 31
8% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 80
1% less funds holding
Funds holding: 207 [Q4 2024] → 204 (-3) [Q1 2025]
3.36% less ownership
Funds ownership: 26.93% [Q4 2024] → 23.57% (-3.36%) [Q1 2025]
10% less capital invested
Capital invested by funds: $3.23B [Q4 2024] → $2.91B (-$324M) [Q1 2025]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 7 (-1) [Q1 2025]
44% less call options, than puts
Call options by funds: $9.37M | Put options by funds: $16.8M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$54
39%
upside
Avg. target
$70
80%
upside
High target
$84
116%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Matthew Harrison | 108%upside $81 | Overweight Maintained | 10 Jul 2025 |
HC Wainwright & Co. Mitchell Kapoor | 93%upside $75 | Buy Reiterated | 8 Jul 2025 |
UBS Ashwani Verma | 39%upside $54 | Buy Maintained | 2 Jul 2025 |
Truist Securities Asthika Goonewardene | 82%upside $71 | Buy Maintained | 14 May 2025 |
Cantor Fitzgerald Rick Bienkowski | 41%upside $55 | Overweight Reiterated | 14 May 2025 |
Financial journalist opinion
Negative
Investors Business Daily
3 weeks ago
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.
Neutral
Accesswire
1 month ago
Legend Biotech Corporation INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Legend Biotech Corporation (LEGN)
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.
Neutral
Accesswire
1 month ago
LEGN STOCK ALERT: Levi & Korsinsky Notifies Legend Biotech Corporation Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.
Neutral
Accesswire
1 month ago
Shareholders That Lost Money on Legend Biotech Corporation (LEGN) Should Contact Levi & Korsinsky about Securities Fraud Investigation - LEGN
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.
Neutral
Accesswire
1 month ago
Levi & Korsinsky Announces an Investigation on Behalf of Legend Biotech Corporation (LEGN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.
Neutral
Accesswire
1 month ago
LEGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Legend Biotech Corporation Shareholders Who Lost Money
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.
Neutral
CNBC Television
1 month ago
Mizuho's Jared Holz details potential biotech, pharma acquisitions
Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.
Neutral
Accesswire
1 month ago
LEGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Legend Biotech Corporation Shareholders Who Lost Money
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.
Neutral
GlobeNewsWire
1 month ago
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with no maintenance or subsequent myeloma therapy. Notably, an unprecedented 33% (32 of 97) of patients remained progression-free for five years or more.
Neutral
Accesswire
1 month ago
LEGN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Legend Biotech Corporation Investment
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.
Charts implemented using Lightweight Charts™